Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) to Post Q2 2022 Earnings of ($0.85) Per Share, Oppenheimer Forecasts

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNTGet Rating) – Equities researchers at Oppenheimer dropped their Q2 2022 earnings per share (EPS) estimates for shares of Opiant Pharmaceuticals in a report released on Wednesday, May 11th. Oppenheimer analyst L. Gershell now expects that the technology company will post earnings per share of ($0.85) for the quarter, down from their prior forecast of ($0.36). Oppenheimer also issued estimates for Opiant Pharmaceuticals’ Q3 2022 earnings at ($0.79) EPS, Q4 2022 earnings at ($0.93) EPS and FY2022 earnings at ($4.54) EPS.

Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Opiant Pharmaceuticals in a research report on Wednesday, March 16th. TheStreet cut shares of Opiant Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Monday, April 18th.

Shares of NASDAQ:OPNT opened at $12.47 on Monday. Opiant Pharmaceuticals has a fifty-two week low of $7.34 and a fifty-two week high of $37.71. The company has a quick ratio of 10.10, a current ratio of 8.72 and a debt-to-equity ratio of 0.35. The company has a market cap of $63.35 million, a PE ratio of -8.60 and a beta of 0.65. The firm has a 50-day simple moving average of $21.16 and a 200 day simple moving average of $25.91.

Opiant Pharmaceuticals (NASDAQ:OPNTGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The technology company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($1.68). Opiant Pharmaceuticals had a negative net margin of 13.70% and a negative return on equity of 15.28%. The business had revenue of $4.47 million for the quarter, compared to the consensus estimate of $7.13 million. During the same period in the prior year, the company earned ($0.66) EPS.

Large investors have recently modified their holdings of the company. Dorsey Wright & Associates acquired a new stake in shares of Opiant Pharmaceuticals in the 4th quarter worth approximately $72,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Opiant Pharmaceuticals in the 4th quarter worth approximately $108,000. Advisor Group Holdings Inc. lifted its stake in shares of Opiant Pharmaceuticals by 102.4% in the 3rd quarter. Advisor Group Holdings Inc. now owns 6,325 shares of the technology company’s stock worth $163,000 after acquiring an additional 3,200 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Opiant Pharmaceuticals in the 4th quarter worth approximately $216,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Opiant Pharmaceuticals by 481.8% in the 4th quarter. JPMorgan Chase & Co. now owns 6,743 shares of the technology company’s stock worth $227,000 after acquiring an additional 5,584 shares during the period. 27.93% of the stock is owned by institutional investors.

Opiant Pharmaceuticals Company Profile (Get Rating)

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.

Read More

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.